Safety and Efficacy of DIDALA Monotherapy in Patients With Type 2 Diabetes Compared With Metformin.
Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label, two-group parallel study, comparing before and after treatment within
the same group and between the two groups. This study is designed to collect data on the
safety and efficacy of a marketed pharmaceutical product (DIDALA) compared with Metformin.
The efficacy data of DIDALA will be directly compared with Metformin 1000mg/day monotherapy
in this study.
Phase:
Phase 3
Details
Lead Sponsor:
Centre of Clinical Pharmacology, Hanoi Medical University